Cocrystal Pharma (8CC) Stock Overview
A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
8CC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Cocrystal Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$0.70 |
| Beta | 1.18 |
| 1 Month Change | 32.58% |
| 3 Month Change | 28.96% |
| 1 Year Change | 10.28% |
| 3 Year Change | -46.36% |
| 5 Year Change | n/a |
| Change since IPO | -53.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8CC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.2% | 1.3% | 2.9% |
| 1Y | 10.3% | 25.4% | 12.1% |
Return vs Industry: 8CC underperformed the German Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: 8CC underperformed the German Market which returned 11.4% over the past year.
Price Volatility
| 8CC volatility | |
|---|---|
| 8CC Average Weekly Movement | 17.6% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 8CC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8CC's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 10 | Sam Lee | www.cocrystalpharma.com |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections.
Cocrystal Pharma, Inc. Fundamentals Summary
| 8CC fundamental statistics | |
|---|---|
| Market cap | €16.81m |
| Earnings (TTM) | -€7.53m |
| Revenue (TTM) | n/a |
Is 8CC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8CC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.06m |
| Gross Profit | -US$5.05m |
| Other Expenses | US$3.78m |
| Earnings | -US$8.83m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8CC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 07:49 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cocrystal Pharma, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Robert LeBoyer | NOBLE Capital Markets, Inc. |
| David Bautz | Zacks Small-Cap Research |